A hospital glucose meter flaw can attach a blood sugar reading to the wrong patient

StatStrip Glucose Hospital Meter Systems, the handheld bedside testers many hospitals use to check patients’ blood sugar, can display a previous patient’s identity after a barcode scan, and a result accepted under that stale identity is filed in the wrong person’s chart. Nova Biomedical, the maker, began a global medical device correction on 24 July 2026, announced it on 5 October, and the Food and Drug Administration published the notice on 6 October.

The company has placed a shipment hold on all StatStrip Glucose Hospital Meter Systems while a software fix is verified, with a phased rollout planned to begin in November 2026.

A stale patient ID after the barcode scan

The mechanism is spelled out in the correction FDA posted. When a staff member scans a patient’s ID barcode, information from the previous patient can remain on the meter screen. If the operator accepts that screen, the glucose result is saved to the wrong patient’s medical record. Nova describes the flaw as a software issue that may cause a glucose result to be “associated with the wrong patient.”

Nova’s own Revised Field Safety Correction, dated 5 October 2026 and marked Rev. 2, adds that the issue does not affect analytical accuracy, so the number the strip measures is correct; what goes wrong is whose record receives it. The notice says the problem applies to all software versions and that critically ill patients and infants face greater risk, because they may be unable to report the symptoms of low blood sugar.

Gen 2.0 meters and the affected part numbers

Only the newest model, commonly called the Gen 2.0 StatStrip, is covered. The earlier Gen 1.0, Gen 1.75, Gen 1.86 and Gen 1.87 meters are not. In the United States the correction names two products, part 63685, the StatStrip Glucose Hospital Meter System, and part 66739, its multipack, both under the device identifier 00385480636858, and it applies to every serial number. Four glucose-and-ketone versions, parts 63683, 63726, 63910 and 66249, are sold outside the United States, including in Japan and Germany, and are covered too.

Nova states that it has received 71 reports of the problem. The FDA-posted text records one adverse event in the United States, on 17 July 2026, a week before the correction began: a patient was given inappropriate insulin based on another patient’s glucose result. Nova says no serious adverse events have been reported and none were reported outside the United States.

Interim safeguards until the update arrives

Nova’s notice sets out what hospitals should do until the software is replaced. Where the electronic medical record feeds admission, discharge and transfer data into the NovaNet middleware, laboratories can turn on “Validate Patient ID’s,” an option available only to those ADT users. In NovaNet’s Logoff Setup, the Operator Logoff Mode can be set to “Test” so the operator signs off after each test. Staff are told to compare the name, date of birth and other identifiers on the Confirm Patient ID screen before accepting a scan, and to check the patient ID again when the result appears rather than assume the two match.

If a result lands on the wrong patient, the notice tells staff to notify an administrator immediately, flag or remove the erroneous entry in the record under facility procedures, and inform the treating team. Hospitals with an alternative device are told to stop using the affected meter; those without one are to keep following the safeguards until the update is installed.

The risks named in the correction are clinical ones: a clinician could act on another patient’s glucose reading, which could mean delayed treatment, unnecessary treatment including inappropriate insulin dosing, or a failure to treat the patient who was actually tested. How much harm follows depends on the patient’s true glucose status and condition, which is why the notice leans so heavily on the two identity checks at the bedside, one at scan and one at result, while the software stays unchanged.

This is not the first time Nova has corrected the same product line. A January 2025 FDA posting described a November 2024 field correction for a different software error, in which results sent wirelessly to hospital records could be wrong if an operator opened the Review Results screen mid-transmission, fixed by software version 0.0.13.45 or later, a notice that Becker’s Hospital Review covered in February 2025 as FDA placed it in the most serious recall category, with no injuries reported. The 2026 defect sits at the patient-identification step instead, and FDA’s page for the new notice does not state a recall classification; FDA’s device recall listing tracks such actions as either an early alert or a confirmed recall.

Nova’s count of 71 reports, against a single documented insulin error, is the number that frames how often the ID mix-up has surfaced before the November update begins.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview